Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 30, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - March 30, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/16 - Castle Creek Pharmaceuticals Announces License of Exclusive U.S. Rights for Arlevert from Hennig Arzneimittel GmbH
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
12/31/16 - Ebola vaccine shows promise An experimental vaccine against Ebola is 100 percent effective in clinical trials
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
12/31/16 - Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial [Saudi Press Agency (Saudi Arabia)]
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
12/31/16 - Pharmacist: New medications help with dry eyes, seizures and hallucinations
In 2016, many new and useful medications got FDA approval. My articles are syndicated worldwide, but I'm only listing English drug names so please ask your local pharmacist to translate the medication name for your country. So the FDA approved this injectable drug to help people who have been exposed from infected animals, contaimated animal produc
12/31/16 - TapImmune: Year End 2016 Update
TapImmune, Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today issued its year-end 2016 update. Below is the statement from Glynn Wilson, Ph.D., Chairman and CEO of TapImmune:. As you are well a
12/30/16 - "Cosmetic and Pharmaceutical Foam" in Patent Application Approval Process (USPTO 20160354473)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Tamarkin, Dov; Friedman, Doron; Eini, Meir, filed on August 16, 2016, was made available online on December 15, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a co
12/30/16 - "Dose Titration Aid" in Patent Application Approval Process (USPTO 20160354536)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Radmer, Bo, filed on February 23, 2015, was made available online on December 15, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Novo Nordisk A/S. The following quote was obt
12/30/16 - "Medical Device Notification System" in Patent Application Approval Process (USPTO 20160354562)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Morrison, Mark Steven, filed on June 3, 2016, was made available online on December 15, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Microdose Therapeutx, Inc.. The followi
12/30/16 - $30M CDI Settlement with Bristol-Myers Squibb Results from Lawsuit by Celebrity Attorney Mychal Wilson
By a News Reporter-Staff News Editor at Insurance Weekly News- Mychal Wilson, Esq., a former actor/producer and top big pharma cardiovascular/diabetes pharmaceutical sales representative announces that he was successful again for blowing the whistle against his former employer and pharmaceutical giant Bristol-Myers Squibb in the groundbreaking...
12/30/16 - 2016 a disappointment for GNC null
The company's shares have plunged by more than 64 percent in 2016 as foot traffic fell at its more than 4,400 U.S. stores and customers cut down on buying vitamins and nutritional supplements. Once a Wall Street darling, GNC's market value has dropped by about $5 billion since its peak in 2013 as it battled slumping sales and aggressive competition
12/30/16 - Acerus Announces NATESTO License Agreement with Hyundai Pharm
By a News Reporter-Staff News Editor at Health& Medicine Week Acerus Pharmaceuticals Corporation announced the signing of an agreement granting the exclusive right to market NATESTO in South Korea to Hyundai Pharm Co., LTD., a South Korean pharmaceutical company. "Hyundai has a proven track record of success in launching products, building ne
12/30/16 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Dec. 12, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on December 12, 2016. The SEC file number is 0001171843-16-013604.. A U.S. Securities and Exchange Commission filing is a for
12/30/16 - ASOP Global, AMA, APhA And 14 Other Groups Join Forces To Educate Healthcare Providers And Patients About Illegal Online Pharmacies
By a News Reporter-Staff News Editor at Health& Medicine Week- The HYPERLINK "http://www.buysaferx.pharmacy/"\ nAlliance for Safe Online Pharmacies is partnering with the American Medical Association, American Pharmacists Association and 14 other HYPERLINK "...
12/30/16 - Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer [Seven Days (United Arab Emirates)]
COPENHAGEN, Denmark, December 29, 2016- Bavarian Nordic A/S today announced the initiation of a clinical trial combining its proprietary cancer immunotherapy candidate, CV301, with the anti-PD-1 drug, OPDIVO from Bristol-Myers Squibb. "We are pleased to announce the initiation of this study, which marks the entry for Bavarian Nordic into lung canc
12/30/16 - BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317
BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of the first patient in a Phase I clinical trial of BGB-A317, an anti-PD-1 monoclonal antibody, in mainland Chinese patients with advanced solid tumors.. We are enthusiastic ab
12/30/16 - Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017
By a News Reporter-Staff News Editor at Drug Week Bristol-Myers Squibb Company will announce results for the fourth quarter of 2016 on Thursday, January 26, 2017. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook. Keywords for this news article include: Pharmaceutical Comp
12/30/16 - Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Dec. 8, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Can-fite Biopharma Ltd. was posted on December 8, 2016. The SEC file number is 0001213900-16-019262.. A U.S. Securities and Exchange Commission filing is a form
12/30/16 - Cardeas Pharma, Seattle, Assigned Patent for Formulations of Aminoglycoside
ALEXANDRIA, Va., Dec. 30 Cardeas Pharma, Seattle, has been assigned a patent developed by Alan Bruce Montgomery, Medina, Washington, for "formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia and ventilator associated tracheal bronchitis." The patent application was fil
12/30/16 - Change in number of shares and votes in Moberg Pharma
The number of shares and votes in Moberg Pharma AB has increased by 3,122,654 in December 2016. The total number of shares and votes has increased as a result of the directed share issue of in total 2,843,504 shares that Moberg Pharma announced on 7 December 2016 and as a result of 279,150 shares issued after exercise of warrants under Moberg Pharm
12/30/16 - Christopher Nowinski Joins Oxeia Biopharmaceuticals Advisory Board
By a News Reporter-Staff News Editor at Energy Weekly News- Oxeia Biopharmaceuticals, Inc., a biotechnology company leading the industry in the development of first-in-class neurometabolic treatments for concussions and brain injury, announced that Christopher Nowinski, co-founder and CEO of the Concussion Legacy Foundation, has joined the compan
12/30/16 - Cti Biopharma Corp. Files SEC Form 8-K, Current Report (Dec. 9, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on December 9, 2016. The SEC file number is 0000891293-16-000201.. A U.S. Securities and Exchange Commission filing is a formal d
12/30/16 - Dr. Dana Carroll to Deliver Keynote on Challenges in Programmable Genome Editing in San Diego
2nd Annual Genome Editing & Engineering Conference to be held on 6th - 7th February 2017 in San Diego, CA will see participation from global experts from pharmaceutical, bio-pharmaceutical companies, universities and academic institutions. The conference will look into various genome editing tools like CRISPR/Cas9 and TALENs and the potential they
12/30/16 - FDA Issues Rule for Withdrawal of Approval of New Animal Drug Applications
WASHINGTON, Dec. 30 The Food and Drug Administration published the following rule in the Federal Register:. A Rule by the Food and Drug Administration on 12/27/2016. Agencies: Food and Drug Administration.
12/30/16 - Findings from University Nova of Lisboa Provides New Data on Antibiotics (Solubility Data as a Response for a Challenge for Formulation Chemists:...
By a News Reporter-Staff News Editor at Drug Week Fresh data on Drugs and Therapies- Antibiotics are presented in a new report. According to news reporting out of Caparica, Portugal, by NewsRx editors, research stated, "The evolution of technology is directed to reduce industrial waste from chemical processes to zero. Our news journalists obtaine
12/30/16 - Global Vitamin Ingredients Market to Grow at a CAGR of 4.71% During 2016-2020
ResearchMoz added Latest Research Report titled "Global Vitamin Ingredients Market 2016-2020: Worldwide Market Size, Shares, Trends, Growth, Survey and Forecast report" to it's Large Report database.Albany, NY 12/30/2016 Vitamins are of two sorts water soluble and fat soluble. Vitamin B can be of the following types B1, B2, B3, B5, B6, B12, B
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415